Influence of dendrimer's structure on its activity against amyloid fibril formation

Biochemical and Biophysical Research Communications

Volumn 345, Issue 1, 2006, Pages 21-28

  Klajnert, B ^a   Cortijo Arellano, M ^b   Cladera, J ^b   Bryszewska, M ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Aggregation; Alzheimer; Amyloid peptide; Dendrimer; Prion

Indexed keywords

AMYLOID BETA PROTEIN [1- 28]; AMYLOID PROTEIN; DENDRIMER; POLYAMIDOAMINE; PRION PROTEIN; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; ELECTRON MICROSCOPY; FLUORESCENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION;

AMYLOID; AMYLOID BETA-PROTEIN; BINDING SITES; DIMERIZATION; MODELS, CHEMICAL; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; PEPTIDE FRAGMENTS; POLYAMINES; PRIONS; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646390727     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.04.041     Document Type: Article

References (32)

1. Supattapone S., Nguyen H.-O.B., Cohen F.E., Prusiner S.B., and Scott M.R. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. USA 96 (1999) 14529-14534
2. Supattapone S., Wille H., Uyechi L., Safar J., Tremblay P., Szoka F.C., Cohen F.E., Prusiner S.B., and Scott M.R. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75 (2001) 3453-3461
3. Solassol J., Crozet C., Perrier V., Leclaire J., Beranger F., Caminade A.M., Meunier B., Dormont D., Majoral J.-P., and Lehmann S. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J. Gen. Virol. 85 (2004) 1791-1799
4. Heegaard P.M.H., Pedersen H.G., Flink J., and Boas U. Amyloid aggregates of the prion peptide PrP 106-126 are destabilised by oxidation and by action of dendrimers. FEBS Lett. 577 (2004) 127-133
5. Caminati G., Turro N.J., and Tomalia D.A. Photophysical investigation of starburst dendrimers and their interactions with anionic and cationic surfactants. J. Am. Chem. Soc. 112 (1990) 8515-8522
6. Tomalia D.A., Naylor A.M., and Goddard III W.A. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew. Chem. Int. Ed. 29 (1999) 138-175
7. Klajnert B., Cortijo M., Bryszewska M., and Cladera J. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases. Biochem. Biophys. Res. Commun. 339 (2006) 577-582
8. Kuznetsov I.B., and Rackovsky S. Comparative computational analysis of prion proteins reveals two fragments with unusual structural properties and a pattern of increase in hydrophobicity associated with disease-promoting mutations. Protein Sci. 13 (2004) 3230-3244
9. Mahfoud R., Garmy N., Maresca M., Yahi N., Puigserver A., and Fantini J. Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J. Biol. Chem. 277 (2002) 11292-11296
10. McLaurin J., Franklin T., Zhang X., Deng J., and Fraser P.E. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem. 266 (1999) 1101-1110
11. Diaz-Nido J., Wandosell F., and Avilla J. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 23 (2002) 1323-1332
12. LeVine III H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 (1993) 404-410
13. Krebs M.R.H., Bromley E.H.C., and Donald A.M. The binding of thioflavin T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149 (2005) 30-37
14. Masel J., and Jansen V.A.A. Designing drugs to stop the formation of prion aggregates and other amyloids. Biophys. Chem. 88 (2000) 47-59
15. Sabaté R., Gallardo M., and Estelrich J. An autocatalytic reaction as a model for the kinetics of the aggregation of β-amyloid. Biopolymers 71 (2003) 190-195
16. Patterson W.J., and Painter M.J. Bovine spongiform encephalopathy and new variant Creutzfeldt Jakob disease: an overview. Commum. Dis. Public Health 1 (1999) 5-13
17. Caughey B., Ernst D., and Race R.E. Congo red inhibition of scrapie agent replication. J. Virol. 67 (1993) 6270-6272
18. Caughey W.S., Raymond L.D., Horiuchi M., and Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phtalocyanines. Proc. Natl. Acad. Sci. USA 95 (1998) 12117-12122
19. Tagliavini F., Forloni G., Colombo L., Rossi G., Girola L., Canciani B., Angeretti N., Giampaolo L., Peressini E., Awan T., De Gioia L., Ragg E., Bugiani O., and Salmona M. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J. Mol. Biol. 300 (2000) 1309-1322
20. Pérez M., Sadqi M., Muñoz V., and Ávila J. Inhibition by aplidine of the aggregation of the prion peptide PrP 106-126 into β-sheet fibrils. Biochim. Biophys. Acta 1639 (2003) 133-139
21. Klajnert B., Stanisławska L., Bryszewska M., and Pałecz B. Interactions between PAMAM dendrimers and bovine serum albumin. Biochim. Biophys. Acta 1648 (2003) 115-126
22. Klajnert B., Sadowska M., and Bryszewska M. The effect of polyamidoamine dendrimers on human erythrocyte membrane acetylcholinesterase activity. Bioelectrochem 65 (2004) 23-26
23. Esler W.P., Stimson E.R., Ghilardi J.R., Felix A.M., Lu Y.A., Vinters H.V., Mantyh P.W., and Maggio J.E. A β deposition inhibitor screen using synthetic amyloid. Nat. Biotechnol. 15 (1997) 258-263
24. Nguyen K.V., Gendrault J.-L., and Wolff C.-M. Poly-l-lysine dissolves fibrillar aggregation of the Alzheimer β-amyloid peptide in vitro. Biochem. Biophys. Res. Commun. 291 (2002) 764-768
25. Ghanta J., Shen C.L., Kiessling L.L., and Murphy R.M. A strategy for designing inhibitors of β-amyloid toxicity. J. Biol.Chem. 271 (1996) 29525-29528
26. Esfand R., and Tomalia D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discovery Today 6 (2001) 427-436
27. Wood S.J., Maleeff B., Hart T., and Wetzel R. Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. J. Mol. Biol. 256 (1996) 870-877
28. Bohrmann B., Adrian M., Dubochet J., Kuner P., Müller F., Huber W., Nordstedt C., and Döbeli H. Self-assembly of β-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J. Struct. Biol. 130 (2000) 232-246
29. Voropai E.S., Samtsov M.P., Kaplevskii K.N., Maskevich A.A., Stepuro V.I., Povarova O.I., Kuznetsova J.M., Turoverov K.K., Fink A.L., and Uverskii V.N. Spectral properties of thioflavin T and its complexes with amyloid fibrils. J. Appl. Spectrosc. 70 (2003) 868-874
30. McLaurin J., Yang D.-S., Yip C.M., and Fraser P.E. Review: modulating factors in amyloid-β fibril formation. J. Struct. Biol. 130 (2000) 259-270
31. Caminade A.-M., and Majoral J.-P. Water-soluble phosphorus-containing dendrimers. Prog. Polym. Sci. 30 (2005) 491-505
32. http://www.dendritech.com/pamam.html.